Vycor Medical, Inc. (OTCQB: VYCO) announced financial results for the year ended December 31, 2025, reporting consolidated revenue of $1,863,400, a 17% increase from $1,589,324 in 2024. The Vycor Medical division, which markets the ViewSite Brain Access System (VBAS), generated $1,796,070 in revenue, up 18% year-over-year, with most growth coming from international markets, a key strategic focus. Gross profit for the division rose to $1,498,295, though gross margin declined to 83% from 89%, attributed to higher manufacturing and shipping costs and a shift in sales mix toward international markets. The NovaVision division, still in development, reported revenue of $67,330, down 8% from 2024, with gross margin improving to 93%.
The company achieved a GAAP operating profit of $33,900, compared to an operating loss of $9,145 in 2024. Non-GAAP operating profit, which excludes non-cash depreciation and stock-based compensation, was $145,881, up from $81,548 in the prior year. On a GAAP basis, net loss available to common stockholders was $396,796, or $0.01 per share, improved from a loss of $431,570 in 2024. Non-GAAP net loss was $284,815, or $0.01 per share, compared to $340,877 in 2024.
During 2025, seven new peer-reviewed studies were published on the VBAS system, bringing the total to 50 peer-reviewed papers and 14 additional clinical papers. The studies originated from the US, UK, Japan, and Mexico, highlighting reduced brain tissue damage, improved patient outcomes, and shorter hospital stays. A new study on NovaVision's NeuroEyeCoach program validated its effectiveness in both home-based and clinic-based settings, supporting the shift toward digital health solutions. For more information on VBAS, see the company's product page.
Vycor Medical continues to focus on expanding its international footprint and advancing clinical evidence for its products. The company's VBAS is used in over 350 US hospitals and internationally, protected by 49 issued and 8 pending patents. NovaVision's Visual Restoration Therapy remains the only FDA-cleared therapy for vision rehabilitation after neurological brain damage. For further details, visit Vycor Medical's website or NovaVision's website.
